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OBJECTIVES: To compare clinical outcomes of type 2 diabetic patients with and
without TZDs therapy after patients receiving DES. METHODS: We conducted a
retrospective cohort study using the National Health Insurance Database (NHIRD).
The type 2 diabetes mellitus patients were included if they received first limus-
eluting stent or paclitaxel-eluting stent placement andwere identified by presence
of a hospital claim during the period fromDecember 1, 2006, through December 31,
2007. Follow-up data were available through December 31, 2008. Patients were
classified into two groups based on the antidiabetic agents they took from phar-
macy records for use of TZD (rosiglitazone, pioglitazone) or non-TZD within 3
months after the index date of hospitalization. A total of 1,743 patients who re-
ceived stents during the study period were identified as the study subjects. Our
measure of effectiveness was the prevalence of death, myocardial infarction and
repeat revascularization, defined as any PCI, whether or not the patient received a
stent, or crossed over to CABG within one year after index hospitalization.
RESULTS: There were 268 patients in TZD group, 1,475 patients in non-TZD group.
Compared with non-TZD group, there were no significant difference in adjusted
hazard ratio of death, myocardial infarction and repeat revascularization between
limus-eluting stent group and paclitaxel-eluting stent group. In stratified analysis,
patients who received limus-eluting stent with history of myocardial infarction
and treated with TZDs were associated with a higher risk of myocardial infarction
(HR 5.292, 95% CI1.028– 27.232). CONCLUSIONS:Our findings suggest that TZDs
could not improve clinical outcomes in type 2 diabetes patients after drug-eluting
stent implantation. TZDs may contribute to higher risk of myocardial infarction in
patientwith limus-eluting stent and history ofmyocardial infarction. For the pleio-
tropic effects of TZDs, balance between benefit and risk for cardiovascular events
to different subgroups, may be different.Further studies are required to investigate
this relationship.
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IS ANEMIA ASSOCIATED WITH HEART FAILURE? NHANES DATABASE (2005-
2006) ANALYSIS
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OBJECTIVES: Anemia is a prevalent public health problem associated with in-
creased risk of morbidity and mortality. It is also associated with cardiovascular
disorders (CVDs) including heart failure (HF). In a large community study, 58% ofHF
patients had anemia. There is a wide variation in the reported prevalence of ane-
mia among HF patients (7%-50%). This community based study investigated
whether anemia is associated with HF using data from National Health and Nutri-
tion Examination Survey (NHANES) which is a national survey to assess the health
and nutritional status in the United States. METHODS: NHANES data from the
2005-2006 administration were combined and analyzed cross-sectionally. Descrip-
tive statistics and univariate comparisons were used as appropriate. Weighted
multivariable logistic regression was used to predict and compute odds ratios (OR)
and 95% confidence intervals (CI) of the association between HF and anemia
prevalence. RESULTS: There were 953 respondents with anemia, and 180 respon-
dents had HF. Among those with anemia, the proportion of African Americans was
significantly higher than Caucasians (46% vs. 31%; p0.001; respectively). Respon-
dentswith anemiawere significantlymore likely to have cancer, other CVDs status,
and be pregnant than those without anemia (p0.001, p0.001, and p0.002, re-
spectively). In addition, prevalence of anemia was significantly higher in respon-
dents with HF as compared to those with other CVDs (18% vs. 4%; p0.001). Ap-
proximately 10% of HF respondents had anemia compared to just 2% among those
without HF (OR5.09, CI 5.08-5.11). This association remained statistically signif-
icant after adjusting for age, race, pregnancy status, cancer, smoking status, and
other CVDs (OR5.8, CI 5.54-5.96). CONCLUSIONS: According to this study, the
prevalence of anemia among HF patients is relatively high. African Americans and
those with HF are more likely to experience anemia. The association between HF
and anemia remained after controlling for confounders.
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CARDIOVASCULAR RISK FACTORS AMONG CHINESE AND WHITE ADULTS IN
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OBJECTIVES: Current prevalence of cardiovascular risk factors are lacking among
Chinese adults. This study contributes to our knowledge by examining current
national estimates for hypertension, high cholesterol, diabetes and obesity among
Chinese and white adults aged 20 years and older, by gender and age group.
METHODS: Cross-sectional observational study design. Analysis of adults 20 years
and older surveyed in the National Health Interview Surveys 2006-2008 (Chinese, n
 853, white, n 51,769). RESULTS: Among US Chinese adults (2.2 million), hyper-
tension and high cholesterol are equally prevalent (19%, age-standardized), but
significantly lower than the 27% age-standardized prevalence of each condition
among the population of US white adults (176 million). Among Chinese and white
adults aged 65 years and older, hypertension rates are similar, 56% and 59%, re-
spectively, but high cholesterol prevalence is significantly lower among Chinese
adults, 33% vs. 49%, respectively, driven by the lower rate of high cholesterol
among older Chinesemen (27%) than older Chinese women (40%). Overall diabetes
prevalence is significantly lower among Chinese than among white adults (5% vs.
7%), but rates among older adults are similar, 16% and 17%, respectively. Obesity
rates for Chinese adults aged 20-39, 40-64, and 65 are 6%, 8%, and 7%, respectively.
Obesity rates for white adults aged 20-39, 40-64, and 65 are 26%, 34%, and 27%,
respectively (p  0.0001 for all obesity differences). CONCLUSIONS: Overall age-
standardized prevalence rates of hypertension, high cholesterol and diabetes are
lower among Chinese adults. However, among older adults, hypertension and diabe-
tes rates are similar in the Chinese and white populations. Obesity rates are lower
among Chinese adults of all age groups. Effective approaches are recommended to
reduce selected cardiovascular risk factors among both groups of older adults.
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OBJECTIVES: Anticoagulation is recommended for atrial fibrillation (AF) patients
withmoderate-high stroke risk and low risk of bleeding. Previous data have shown
that bleeding rates increase in parallel with stroke risk because stroke and bleeding
risk factors overlap. The objective of this study was to assess whether adding
ATRIA specific bleeding risk variables to the CHADS2 stroke risk variables will
improve the ability to predict major bleeds. METHODS: Medical claims for AF pa-
tients (ICD-9 code 427.31) with continuous eligibility 12 months prior to an AF
diagnosis in the MarketScan database between January 2003 to December 2007
were analyzed. Data before an index AF diagnosis were used to assess the presence
of CHADS2 (congestive heart failure, hypertension, age 75, diabetes, prior stroke/
transient ischemic attack) and ATRIA (anemia, renal disease, age 75, prior bleed-
ing, hypertension) risk factors. The Pearson correlation coefficient between the
CHADS2 and ATRIA risk scores and Cox proportional hazards regressions compar-
ing a reduced model (CHADS2 covariates only) and a full model (CHADS2  ATRIA
covariates) to predict major bleeds after an AF diagnosis were estimated. Likeli-
hood ratio tests were used to test for differences between the models. RESULTS: A
total of 64,946 AF patients were included in the analysis (47%75 years of age, 45%
females). ATRIA and CHADS2 scores were correlated (r0.63, p0.0001). CHADS2
risk factors predicted major bleeding (LR444.66, P0.001). The addition of ATRIA
risk factors enhanced predictive power (LR519.65, P0.001) and resulted in a sig-
nificant improvement in model fit (P0.001). A range of sensitivity analyses re-
vealed similar findings. CONCLUSIONS: Adding ATRIA bleeding risk factors to the
CHADS2 significantly improved the model fit. These results suggest that informa-
tion provided by the ATRIA bleeding risk index improves bleeding risk assessment
and may potentially help optimize anticoagulation decisions. Further research is
needed to assess improvements in model discrimination.
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OBJECTIVES: Passive smoking is accountable each year for approximately 53,000
and 22,000 deaths in the United States and Europe. The aim of this study was to
conduct a meta-analysis of cohort and case-control studies to determine risk fac-
tors to show cardiovascular events and stroke in passive smokers. METHODS: A
systematic review was conducted in February 2010 through Medline, EMBASE, and
the Cochrane Collaboration. Selection criteria variables were: case-control, cohort
and cross-sectional studieswere all studiesmust include exposed and not exposed
subjects to environmental tobacco smoke. Two independent reviewers identified
the abstracts, selected the full articles, and extracted the data. Odds ratios (OR) and
weighted means differences were calculated. Random effects models were em-
ployed in the analyses with each of the estimated variables with Meta-Analysis v.2
software. RESULTS: A total of 821 studies were reviewed and 39 trials were finally
selected. 18/39 studieswere case-control studies, 16/39 studieswere cohort studies
and 5/39 were cross-sectional studies; 29/39 assessed cardiovascular events and
18/39 studies assessed stroke events. Three different tobacco smoke exposure
measurements were defined:1) 17/39 studies were related to spouse smoking hab-
its; 2) 18/39 were according to home and closed spaces behavior exposures; and 3)
4/39 were clinical measurements (serum levels of nicotine or nicotine metabolite).
Relative Risk (RR) to develop a cardiovascular event for passive smokers in case-
control studies (1.466; CI95% 1.301-1.651, p0.001) was higher in comparison to
cross-sectional studies (OR 1.264; 1.203-1.327, p0.001). RR to develop stroke events
was also higher for cohort studies (RR 1.253; 1.038-1.513, p0.019) compared to
case-control studies (OR 1.442; 1.280-1.625, p0.001). No meaningful differences
were found between male/female populations. CONCLUSIONS: Passive smoking
increases the risk to develop a cardiovascular event or stroke by approximately
30%. Health care policymakers should consider these results to implement policies
that enhance exposure reduction of environmental tobacco smoke.
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OBJECTIVES: To determine association between heart failure (HF) and in-hospital
mortality in ST-elevation myocardial infarction (STEMI) patients treated with Per-
cutaneous Coronary Intervention (PCI).METHODS: Retrospective analysis of I3 In-
Vision Data Mart (2003-08). Adult enrollees (18 years) with primary diagnosis of
STEMI were selected if they were a) treated using PCI procedure and b) had contin-
uous enrollment for at least 6 months prior to the STEMI-related index hospital-
ization (baseline). Enrollees were excluded if they underwent coronary artery by-
pass graft during index hospitalization. In-hospitalmoralitywas assessed based on
an algorithm using claims data (or lack thereof) for STEMI patients after index
hospitalization. Pre-existing HF was defined as presence of a claim with relevant
HF diagnosis at baseline. NewonsetHFwas defined as listing of HF as a comorbidity
in the reimbursement claims for index hospitalization without supporting evi-
dence for pre-existing HF at baseline. Multivariate logistic regression was used to
assess association between HF status and in-hospital mortality. Priori significance
level of 0.05 was used for these analyses. RESULTS: Overall 7261 enrollees were
included in the analysis. Out of these, 187 (2.6%) had HF at baseline and 1,075
(14.8%) experienced HF for the first time. Out of 7261 enrollees, 351 (4.8%) died
during index hospitalization. Chances of in-hospital mortality increased signifi-
cantlywith either pre-existingHF (absolute rate (AR): 9.6%, Odds Ratio (OR): 2.3, 95%
Wald confidence limits (CI): 1.0 - 5.4), new onset HF (AR: 10.7%, OR 3.0, 95% CI: 2.3 -
3.8) or inclusion of pre-existing HF as amajor comorbidity (AR: 16.7%, OR 3.9, 95%
CI: 2.2 - 6.9) in index hospitalization claims. CONCLUSIONS: Presence of HF, re-
corded as either a pre-existing condition or as a major comorbid condition, in
STEMI patients undergoing PCI was associated with significant increase in the
in-hospital mortality.
Cardiovascular Disorders – Cost Studies
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BUDGET IMPACT ANALYSIS OF INCREASING LMWH/FXI UTILIZATION
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OBJECTIVES: Lowmolecular weight heparins (LMWH) and factor Xa inhibitors (FXI)
are used to treat and prevent venous thromboembolic events (VTE) andmyocardial
infarctions (MI). Althoughhospitalized patients have increasedVTE/MI risk, almost
60% do not receive appropriate LMWH/FXI medication. Increasing LMWH/FXI uti-
lization while containing costs has become an important quality improvement
goal. Our objective was to estimate from the hospital perspective the annual inpa-
tient costs of increasing LMWH/FXI utilization.METHODS:We developed a budget
impactmodel incorporating event costs of deep vein thrombosis (DVT), pulmonary
embolism (PE), and MI, and pharmacy costs for two LMWH products (dalteparin
sodium injection and enoxaparin sodium injection) and one FXI (fondaparinux).
Inpatient event costs were estimated from AHRQ data at $10,000, $20,000, and
$9,000 for preventable DVT, PE, and MI events, respectively, and inpatient product
costs were estimated using 2010 wholesale acquisition costs with market-based
estimates of current product discounts. Changes in event, pharmacy, and total
hospital costs were estimated for a hypothetical 500-bed hospital in which LMWH/
FXI utilization increased from 60% to 80%, and market share followed two scenar-
ios: maintaining current LMWH/FXI share (90% enoxaparin, 0% dalteparin) or com-
plete formulary interchange from enoxaparin to dalteparin. RESULTS: Increasing
LMWH/FXI utilization from 60% to 80% with unchanged market share would de-
crease costs of DVT by $153,000 (5.5% reduction); PE by $25,000 (6.3%); and MI by
$12,000 (2.4%). Pharmacy costs would correspondingly increase by $308,000 (33.3%)
for a net increase in total hospital costs (event plus pharmacy costs) of $117,000
(2.5%). Alternatively, increasing utilization while also shifting product market
share to greater dalteparin and less enoxaparin use would reduce the pharmacy
cost increase to $208,000 (22.5%), for a net cost increase of $17,000 (0.4%).
CONCLUSIONS: Hospitals could potentially improve treatment quality by increas-
ing appropriate LMWH/FXI utilization, and by shifting utilization from enoxaparin
to dalteparin.
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OBJECTIVES: Different cost components (charges, costs, payments) are required to
estimate the economic impact of a drug therapy on inpatient care from a hospital
and a health plan (payer) perspective. To estimate different cost and payments for
acute coronary syndrome (ACS) inpatient care from different payer (hospital vs.
health plan) and benefit design [Fee-for-Service (FFS) vs. Prospective Payment Sys-
tem (PPS)] perspectives. METHODS: ACS discharges were identified using diagno-
sis-related group (DRG) codes using two data sources: 1) 2008 MarketScan admin-
istrative claims for health plan payments, and 2) 2008 Healthcare Cost and
Utilization Project Nationwide Inpatient Sample (NIS) for hospital charge data.
Admissions were classified as myocardial infarction (MI), unstable angina (UA), per-
cutaneous transluminal intervention (PCI), coronary artery bypass graft (CABG), and
stroke. Cost-to-charge ratios were used to estimate cost to the hospital. MarketScan
data were used to provide payments from payers based on different benefit designs
(PPS, FFS, Medicare and commercial coverage). Cost and payment components were
estimated at each DRG level and for individual ACS events. RESULTS: For ACS dis-
charges (NIS n109,903, MarketScan n85,962), an admission with both PCI and
CABG incurred highest hospital cost/plan payment ($43,867/$65,543) and UA in-
curred lowest ($4,369/$5,576). Hospital charges were consistently higher than plan
payments (e.g., PCI: $52,256 vs. $22,828), whereas estimated hospital costs were
consistently lower than payments (e.g., PCI: $15,902 hospital cost vs. $22,828 pay-
ments). Medicare payments were consistently lower than commercial payments
(e.g., PCI: $17,205 vs. $22,828). Detailed charges, costs, and payments estimates for
various ACS events will be presented. CONCLUSIONS: These ACS inpatient cost
estimates from hospital and health plan perspectives and for different benefit
designs will facilitate economic evaluations of ACS drug therapies. The analytic
approach demonstrated the feasibility and validity of using different secondary
data sources to estimate inpatients costs for various payer types and benefit de-
signs.
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OBJECTIVES: To examine the prophylaxis use, incidence of VTE, major bleeding,
minor bleeding and associated economic burden over 90 days in hospitalizedmed-
ically-ill patients.METHODS: A retrospective study (January 01, 2005 to December
31, 2007) was conducted using a subset of the MarketScan Hospital Drug Database
and its linked outpatient files from the Market Scan Commercial and Medicare
Supplemental database. Eligible patients were selected if they were continuously
enrolled in their health plan for at least 180 days prior to and 90 days following the
index hospital discharge date, which is hospitalization with amedically ill diagno-
sis. Prophylaxis use is defined as the admission date of index hospitalization to 30
days after index hospital discharge and before the date of their first VTE events.
Patients’ demographics, healthcare visits and costs were compared using Chi-
square testing and standardized differences. Risk-adjusted total healthcare costs
betweenpatientswith events andwithoutwere estimated using theGeneral Linear
Model. RESULTS: In patients who were identified as medically ill (n12,077), 6,464
(53.52%) received anticoagulant therapy during their hospitalization and until 30
days after discharge. Compared with patients who did not receive any anticoagu-
lant prophylaxis, patients who received anticoagulant prophylaxis had signifi-
cantly lower VTE events (1.47% vs. 3.58%, p0.0001). Although there was no signif-
icant difference in rates of major bleeding and minor bleeding, after risk-
adjustment for pre-specified covariates, patients with outcome events were
significantly associated with higher total healthcare costs (VTE: $40,523 vs. $17,698
p0.0001; Major bleeding: $27,430 vs. $18,137 p0.0001; Minor bleeding: $25,696 vs.
$17,410 p0.0001). CONCLUSIONS: Despite existing guidelines, few medically-ill
patients are receiving anticoagulant prophylaxis. Appropriate anticoagulant pro-
phylaxis use results in lower VTE event rates and total follow-up healthcare costs
in hospitalized medically-ill patients.
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COMPARISON OF MAJOR BLEEDING RELATED MORTALITY, HEALTH CARE
UTILIZATION AND COSTS OF PATIENTS WITH NON-VALVULAR ATRIAL
FIBRILLATION
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OBJECTIVES: To compare mortality, healthcare utilization and cost burden of pa-
tients who suffered major bleeding during the 180 days after diagnosis of non-
valvular atrial fibrillation (NVAF) with patients who did not. METHODS: Based on
the 2005-2007U.S.Medicare advantage insurance claimfiles, patients aged 65 years
and older who have had two ormore primary diagnoses for NVAF occurring within
30 days of one another were selected. The 180-day follow-up mortality, healthcare
facility use and costs for patients with andwithoutmajor bleedingwere compared.
Risk adjustment was performed using the propensity scorematchingmethodwith
the ProbChoice™algorithm.RESULTS:Out of the patientswhowere identifiedwith
NVAF (n18,575), 266 (1.43%) suffered a major bleeding during the 180 days after
NVAFdiagnosis. Patientswere not significantly different in terms of gender, region,
and baseline comorbid conditions. After risk-adjustment for pre-specified covari-
ates, mortality (9.77% vs. 0.38% p0.0001), outpatient emergency room (ER) visits
(84.21% vs. 43.23% p0.0001), ischemic stroke (44 vs. 8/100 person years), myocar-
dial infarction (10 vs. 2/100 person years) and osteoporotic fracture (7 vs. 1/100
person years) were all higher for patients who suffered amajor bleeding compared
to those who did not. Besides inpatient costs ($26,568 vs. $8,929), risk-adjusted
outpatient ER costs ($1,280 vs. $744) were also higher for major bleeding patients.
The overall risk-adjusted difference in healthcare costs is significant ($35,691 vs.
$10,480 p0.0001). CONCLUSIONS: Most of the adverse events analyzed were
higher for patients who suffered a major bleeding after NVAF relative to patients
who did not. Total healthcare utilization and costs were also significantly in-
creased.
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EVALUATION OF THE HOSPITAL RESOURCE UTILIZATION ASSOCIATED WITH
TOLVAPTAN USAGE AMONG HEART FAILURE PATIENTS WITH HYPONATREMIA
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OBJECTIVES: Tolvaptan is an orally administered selective vasopressin V2-recep-
tor antagonist for hyponatremia treatment. The Efficacy of Vasopressin Antago-
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